Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Hlib Chabaniuk
Hlib Chabaniuk

Vertex Pharmaceuticals enters reimbursement agreement for cystic fibrosis therapy after muted trading session

Vertex Pharmaceuticals enters reimbursement agreement for cystic fibrosis therapy after muted trading session
Vertex Pharmaceuticals stock edges higher today

Vertex Pharmaceuticals has entered a new reimbursement agreement for its latest cystic fibrosis therapy in Estonia, announced September 11, 2026. Separately, the stock edges higher on the day, trading at $515.06.

VRTX price prediction
24H 0.25%
$560.91
48H 0.41%
$561.83
7D 0.36%
$561.52
1M 5.79%
$591.94
3M 12.34%
$628.54
6M 11.13%
$621.79
12M 25.78%
$703.78
Detailed
Current price: $559.52 19.52 3.61%
Closed 10/30
Daily range 553.10 Arrow from to Icon 561.97
Weekly range 509.53 Arrow from to Icon 561.97
Loading...

Highlights

  • Vertex Pharmaceuticals finalized a reimbursement agreement in Estonia for its latest cystic fibrosis therapy for patients aged 6 and older, effective October 1, 2026.
  • Shares of Vertex Pharmaceuticals edged higher, trading at $515.06.
  • 98 of 122 analysts rate the stock a buy, with a median price target of $575, 11.6% above current levels.

Vertex Pharmaceuticals has entered a new reimbursement agreement for its latest cystic fibrosis therapy in Estonia. The agreement enables broad access to eligible people with cystic fibrosis aged 6 years and older starting October 1, 2026. The company made the announcement.

Partial gains hold as consolidation builds above MA-50 support

The session opened with a gap up from $510.72 to $521.64, but price has since given back part of that advance. Shares of Vertex Pharmaceuticals are trading within a split daily structure, holding above the MA-50 but below the MA-20 and above the MA-200. Stoch RSI remains in oversold territory, a stretched reading that limits room for further downside. The nearest support is the MA-50 at $511.82, which helps define the lower boundary of near-term consolidation.

Upside odds lead as weekly structure favors further advance

Traders will be watching for a close above $525.97 to confirm that buyers are positioned to extend the advance, or a drop below $511.82 to show the move is being faded. Shares opened higher at $521.64 compared to the previous close of $510.72, followed by a partial retracement during the session. The recent move has remained contained within a narrow range over the past week; still, there is a 64% probability of upside versus 36% downside for the coming trading week, with the expected range set between $503.89 and $526.22. On the weekly chart the longer-term picture stays firmly constructive.

Previously it was reported that Vertex Pharmaceuticals was showing a mixed technical structure, with investors watching for signs of momentum following clinical trial updates. The latest reimbursement agreement in Estonia and recent price action further bolster the longer-term constructive outlook, with traders now focused on whether shares can maintain support above the MA-50 at $511.82 as a signal for continued consolidation or a potential breakout.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

How German metalworkers’ strikes are testing Europe’s industrial strength
  • By Dmytro Kharkov
  • 1 hour ago
How German metalworkers’ strikes are testing Europe’s industrial strength
Editors' Picks
DeFi for the select few: Why Hyperliquid is building restricted markets
  • By Pavlo Kot
  • Yesterday
DeFi for the select few: Why Hyperliquid is building restricted markets
Editors' Picks
Can Bitcoin make you a millionaire?
  • By Pavlo Kot
  • 31.10.2026
Can Bitcoin make you a millionaire?
Editors' Picks
All Editors' Top Picks

Latest Vertex Pharmaceuticals News

Vertex Pharmaceuticals announces $10 billion acquisition: Can VRTX reverse weak momentum?
  • By Jainam Mehta
  • 13.10.2026
Vertex Pharmaceuticals announces $10 billion acquisition: Can VRTX reverse weak momentum?
Stocks
#Forecast #Vertex Pharmaceuticals
VRTX drops as $10B Crinetics Pharmaceuticals acquisition raises risk
  • By Anton Kharitonov
  • 01.10.2026
VRTX drops as $10B Crinetics Pharmaceuticals acquisition raises risk
Stocks
#Forecast #Vertex Pharmaceuticals
Vertex Pharmaceuticals announces positive study results and trial enrollment after muted trading session
  • By Yaroslav Dmytrenko
  • 22.09.2026
Vertex Pharmaceuticals announces positive study results and trial enrollment after muted trading session
Companies
#Vertex Pharmaceuticals
All Vertex Pharmaceuticals News
  • Dmytro Kharkov
  • 1 hour ago
How German metalworkers’ strikes are testing Europe’s industrial strength
  • Pavlo Kot
  • Yesterday
DeFi for the select few: Why Hyperliquid is building restricted markets
  • Pavlo Kot
  • 31.10.2026
Can Bitcoin make you a millionaire?
  • Olena Litvinenko
  • 30.10.2026
France's crypto market matures as regulation reshapes the industry
  • Dmytro Kharkov
  • 30.10.2026
SK Hynix’s rise reshapes the global chip industry and economy
  • Pavlo Kot
  • 12 min ago
Switching from USDT to betting was nearly instant, Sjuul Follings notes
  • Igor Krasulya
  • 27 min ago
Tracy Shuchart: Goldman Sachs raises crude oil price forecasts on higher supply risks
  • Elena Nikulina
  • 1 hour ago
Crypto and stablecoin transaction tax approved by slim margin, Gregory Raymond notes
  • Mikhail Vnuchkov
  • 1 hour ago
Robert Peston: Questions raised on growth and debt reduction plans in budget discussion
  • Mykhailo Ihnatenko
  • 1 hour ago
Ethereum offers neutrality and censorship resistance, Joseph Lubin states
Top News
  • Andrey Mastykin
  • 45 min ago
Anthropic taps Japanese investors ahead of major U.S. listing as AI financing expands
Anthropic taps Japanese investors ahead of major U.S. listing as AI financing expands
  • Olga Shendetskaya
  • 1 hour ago
Gulf states urge Washington to avoid new confrontation with Iran
Gulf states urge Washington to avoid new confrontation with Iran
  • Eugene Komchuk
  • 2 hours ago
Binance customers withdraw $5.8 billion in wake of hack
Binance customers withdraw $5.8 billion in wake of hack
  • Jose Antonio Gastelum
  • 21 hours ago
OPEC set to hold oil quotas as Middle East risks constrain supply
OPEC set to hold oil quotas as Middle East risks constrain supply
  • Ezequiel Gomes
  • 23 hours ago
Big Tech selloff drives investors back toward U.S. Treasuries
Big Tech selloff drives investors back toward U.S. Treasuries
Live News
  • Mykhailo Ihnatenko
  • Now
Ethereum price struggles above $2,300 despite $63M whale purchase
  • Andrey Mastykin
  • Now
Eurozone economy slows as France slips into recession fears
  • Anton Kharitonov
  • Now
EUR/USD recovery stalls near 1.1210 as dollar retains its fundamental advantage
  • Anastasiia Chabaniuk
  • Now
Binance launches stolen asset recovery and allocates $6.34 billion to cover losses
  • Mykhailo Ihnatenko
  • Now
AMD stock drops over 7% as Intel outlook hits semiconductor sentiment
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers